1. Medtech Insight
  2. >>Device Area
  3. >>Cardiology

FDA Warns: Implantable Devices May Flip To ‘Magnet Mode’ When Near Cell Phones, Smart Watches

 
• By Shawn M. Schmitt

The magnetic field of cell phones and smart watches may be strong enough to switch pacemakers and other implanted medical devices to “magnet mode,” impeding their function, the US FDA says, noting that the risk to patients is low.

Magnet.

The US Food and Drug Administration is warning that the magnetic field of cell phones and smart watches may be strong enough to flip pacemakers and other implanted devices to “magnet mode,” impeding their function.

The mode is designed into the devices so people can safely undergo medical procedures such as an MRI scan.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiology

More from Device Area

Digital Health Roundup: Synchron Syncs With Apple, Ketryx’s AI Agents, AdvaMed’s AI RoadMap

 
• By Marion Webb, Brian Bossetta, Natasha Barrow, Elizabeth Orr, and Shubham Singh

In this week's Digital Health Roundup, MedTech Insight's Shubham Singh explores how Ketryx's launch of validated AI agents could reshape compliance automation in medtech. Marion Webb highlights news from BCI makers Synchron, Axoft and Subsense. Elizabeth Orr discusses AI advances at the FDA.

Guardant’s Multi-Cancer Detection Test Granted FDA Breakthrough Device Designation

 
• By Natasha Barrow

Guardant Health’s methylation-based blood test – Shield MCD – showed a specificity of 98.6% and sensitivity of 75% across eight cancer types in its clinical validation data presented at ASCO.

GE HealthCare Announces US Launch Of Longer Half-Life PET MPI Agent For Ischemia Detection

 
• By Shubham Singh

GE HealthCare is pursuing a dual-front imaging strategy with its PET MIP agent Flyrcado for detecting artery disease: It lasts longer than current PET scan tracers and allows patients to do treadmill-based stress tests alongside the scan.